KASEY GROSS: Open Payments
NPI 1992944607 · ATTALLA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,709 in 92 payments from 10 companies in 2025. Trend: 2023 $1,219 · 2024 $1,512 · 2025 $1,709
Food & beverage: $1,709
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $476 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $353 |
| E.R. Squibb & Sons, L.L.C. | 9 | $202 |
| Alkermes, Inc. | 11 | $197 |
| Lundbeck LLC | 6 | $117 |
| Teva Pharmaceuticals USA, Inc. | 6 | $105 |
| Janssen Pharmaceuticals, Inc | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| ABBVIE INC. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
Products named: INGREZZA, CAPLYTA, COBENFY, ARISTADA, ABILIFY MAINTENA, FANAPT, INVEGA SUSTENNA, VRAYLAR.
Industry payments across AL — which companies pay providers there.
